|Brevard ophthalmologist: Multiple sclerosis affects vision|
Optic neuritis is frequently the first manifestation of MS. Half of all individuals diagnosed with MS initially complained about a vision problem. Up to 75 percent of female patients and 35 percent of male patients diagnosed with optic neuritis ...
Florida Today - Wed, 24 Jun 2015 21:10
|Research and Markets: Optic Neuritis - Pipeline Review, H1 2015|
This report provides comprehensive information on the therapeutic development for Optic Neuritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and ...
Digital Journal - Mon, 22 Jun 2015 07:14
|Biogen Partners with AGTC to Develop Gene Therapies for Eye Diseases|
... the company presented Phase II data showing its Anti-LINGO-1 (BIIB033), a treatment candidate for multiple sclerosis, showed statistically significant improvement in remyelinating damaged neurons, and thus could potentially treat acute optic neuritis.
Genetic Engineering & Biotechnology News - Thu, 02 Jul 2015 07:05
|Biogen Strikes Gene Therapy Partnership Worth About $1 Billion|
San Diego Source (subscription) - Thu, 02 Jul 2015 05:45
|Optic Neuritis and Multiple Sclerosis, What You Should Know|
Optic neuritis (also called demyelinating optic neuritis) is inflammatory demyelination of the optic nerve. Symptoms include vision loss (which can be permanent in some cases), seeing flashing or flickering lights, eye pain with eye movement, and loss ...
eMaxHealth - Thu, 30 Apr 2015 14:55
|Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data ...|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study to demonstrate remyelination (the formation of new ...
Business Wire (press release) - Tue, 14 Apr 2015 13:03
|Biogen Reports New Data from Acute Optic Neuritis Study|
Zacks.com - Wed, 15 Apr 2015 14:12
|Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test|
Forbes - Tue, 14 Apr 2015 13:00
|Stock Update: Biogen Idec Inc (NASDAQ:BIIB) - Biogen Presents New Anti ...|
Jutia Group - Tue, 14 Apr 2015 16:30
|Antiseizure Drug Helps Optic Neuritis in Multiple Sclerosis|
The relationship between seizures, optic neuritis, and multiple sclerosis may seem difficult to fathom, but the results of a new study shed some light on the subject. It appears that the common antiseizure drug called phenytoin has the ability to help ...
eMaxHealth - Thu, 23 Apr 2015 07:14
|Seizure Medication Reduced Optic Neuritis In Multiple Sclerosis|
Medical Research News and Interviews on MedicalResearch.com (blog) - Thu, 23 Apr 2015 12:52
|Epilepsy Drug May Treat Eye Complications in Patients With MS|
Multiple Sclerosis News Today - Wed, 22 Apr 2015 08:37
|Biogen Idec anti-LINGO-1 data in acute optic neuritis whet appetites for more|
Disclosure of top-line data on Biogen Idec Inc.'s anti-LINGO-1 monoclonal antibody (MAb), BIIB033, in acute optic neuritis (AON) so captivated the analyst community that they might have been mistaken for scrutinizing a grand slam emerging from a ...
BioWorld Online - Thu, 08 Jan 2015 18:37
|Biogen Reveals Positive Data from Acute Optic Neuritis Study|
Zacks.com - Fri, 09 Jan 2015 13:33
|Limited Success With Myelin Rebuilder in Optic Neuritis|
MedPage Today - Thu, 08 Jan 2015 10:11
|Biogen's Nerve Repair Drug Yields Mixed Results in Key Eye Trial|
TheStreet.com - Thu, 08 Jan 2015 05:35
|Biogen shares fall after optic nerve study results seen as mixed|
Reuters - Thu, 08 Jan 2015 05:11
|Biogen's anti-LINGO shows mixed results in study|
CNBC - Thu, 08 Jan 2015 05:40
|Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial ...|
FierceBiotech - Thu, 08 Jan 2015 06:15
|MedDay Reveals Promising Data on Progressive Multiple Sclerosis Therapy|
“A second phase III placebo-controlled trial is underway looking at the effect of MD1003 in MS patients with permanent visual loss following optic neuritis and we look forward to announcing data from this trial later this year and potentially ...
Multiple Sclerosis News Today - Tue, 23 Jun 2015 05:28